Complete remission of necrobiotic xanthogranuloma after disappearance of monoclonal immunoglobulin induced by bortezomib, lenalidomid and dexamethasone.
FDG-PET/CT dokumentované vymizení nekrobiotického xantogranulomu při potlačení tvorby monoklonálního imunoglobulinu bortezomibem, lenalidomidem a dexametazonem Popis případu a přehled literatury o léčbě nekrobiotického xantogranulomu.
Kahler-Pick law
Multiple myeloma
monoclonal gammopathy
necrobiotic xanthogranuloma
Journal
Vnitrni lekarstvi
ISSN: 0042-773X
Titre abrégé: Vnitr Lek
Pays: Czech Republic
ID NLM: 0413602
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
23
4
2022
pubmed:
1
1
2021
medline:
27
4
2022
Statut:
ppublish
Résumé
Necrobiotic xanthogranuloma (NXG) is a rare chronic condition, belonging to the group non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly monoclonal gammopathy, MGUS and multiple myeloma. The case reported here NXG was diagnosed after 1 years of evolution in patient with asymptomatic multiple myeloma. After treatment with bortezomib, lenalidomid and dexamethasone, there was evident abrupt decrease of monoclonal immunoglobulin to not measurable level (complete remission of multiple myeloma) and in the same time was evident disappearance of cutaneous and hepatic lesions of NXG on FDG-PET/CT. The etiopathogenetic association of monoclonal immunoglobulin with NXG is documented in this case report with disappearance of NXG in the time of disappearance of monoclonal immunoglobulin.
Substances chimiques
Immunoglobulins
0
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM